Immunotherapy in Head and Neck Cancer.

Head and neck cancer (HNC) is the seventh most common cancer worldwide, with incidence growing every year. While the standard regimen of surgery, chemotherapy, radiotherapy, targeted anti-EGFR therapy, and immune checkpoint inhibition are effective in a subset of patients, therapeutic resistance is a persistent challenge for managing this disease. The use of immunotherapeutic agents to treat HNC has risen over recent years, with advances in immune checkpoint inhibition, targeted therapy with bispecific antibodies, modified cytokine delivery, adoptive cell therapy, and virus-based therapeutics making their way into clinical trials for HNC. This chapter also discusses ongoing investigations into combinatorial strategies and biomarkers aimed at improving outcomes for patients with HNC.